Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

Similar articles for PubMed (Select 12902911)

1.

Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis.

Kramer K, Kushner BH, Cheung NK.

J Pediatr Hematol Oncol. 2003 Aug;25(8):601-5.

PMID:
12902911
2.

Oral etoposide for refractory and relapsed neuroblastoma.

Kushner BH, Kramer K, Cheung NK.

J Clin Oncol. 1999 Oct;17(10):3221-5.

PMID:
10506622
4.

Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.

Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano GM, De Sio L, Cozza R, Fidani P, Deb G, De Laurentis C, Inserra A, Dominici C.

Acta Paediatr Suppl. 2004 May;93(445):6-11.

PMID:
15176712
5.

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.

Saylors RL 3rd, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, Harris MB, Hayashi R, Vietti TJ; Pediatric Oncology Group.

J Clin Oncol. 2001 Aug 1;19(15):3463-9.

PMID:
11481351
6.
7.

Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

Younes A, Preti HA, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA, Samuels BI, Palmer JL, Cabanillas F.

Ann Oncol. 2001 Jul;12(7):923-7.

8.

Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.

Hawkins DS, Bradfield S, Whitlock JA, Krailo M, Franklin J, Blaney SM, Adamson PC, Reaman G.

Pediatr Blood Cancer. 2006 Nov;47(6):790-4.

PMID:
16435380
9.

A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.

Garaventa A, Luksch R, Biasotti S, Severi G, Pizzitola MR, Viscardi E, Prete A, Mastrangelo S, Podda M, Haupt R, De Bernardi B.

Cancer. 2003 Dec 1;98(11):2488-94.

10.

Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

Kushner BH, Kramer K, Modak S, Cheung NK.

J Clin Oncol. 2006 Nov 20;24(33):5271-6.

11.

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.

Di Giannatale A, Dias-Gastellier N, Devos A, Mc Hugh K, Boubaker A, Courbon F, Verschuur A, Ducassoul S, Malekzadeh K, Casanova M, Amoroso L, Chastagner P, Zwaan CM, Munzer C, Aerts I, Landman-Parker J, Riccardi R, Le Deley MC, Geoerger B, Rubie H.

Eur J Cancer. 2014 Jan;50(1):170-7. doi: 10.1016/j.ejca.2013.08.012. Epub 2013 Sep 7.

PMID:
24021349
12.

Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.

Donfrancesco A, De Ioris MA, McDowell HP, De Pasquale MD, Ilari I, Jenkner A, Castellano A, Cialfi S, De Laurentis C, Dominici C.

Pediatr Blood Cancer. 2010 Jan;54(1):55-61. doi: 10.1002/pbc.22219.

PMID:
19821523
13.

Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors.

Bowers DC, Aquino VM, Leavey PJ, Bash RO, Journeycake JM, Tomlinson G, Mulne AF, Haynes HJ, Winick NJ.

Pediatr Blood Cancer. 2004 Jan;42(1):93-8.

PMID:
14752800
14.

Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).

Children's Oncology Group (CCG 09709), Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP.

J Clin Oncol. 2006 Jul 20;24(21):3423-30. Erratum in: J Clin Oncol. 2006 Sep 1;24(25):4223. Reynolds, Patrick C [corrected to Reynolds, C Patrick].

15.

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.

Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM, Alvarez RD.

Gynecol Oncol. 2004 Dec;95(3):564-9.

PMID:
15581964
16.

Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.

Gronlund B, Hansen HH, Høgdall C, Engelholm SA.

Cancer. 2002 Oct 15;95(8):1656-62.

17.

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.

Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, Dryer ZA, Kurtzberg J, Bell B, Grier H, Vietti TJ.

J Pediatr Hematol Oncol. 1996 Nov;18(4):352-61.

PMID:
8888741
18.

Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study.

Längler A, Christaras A, Abshagen K, Krauth K, Hero B, Berthold F.

Klin Padiatr. 2002 Jul-Aug;214(4):153-6.

PMID:
12165894
19.

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study.

Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C.

J Pediatr Hematol Oncol. 1998 Jul-Aug;20(4):315-8.

PMID:
9703003
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk